News and Press Releases
Press releases
Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer
Press ReleaseV.TLT |August 28, 2024 Toronto, Ontario – Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, ra...
Theralase® Demonstrates Unique Ability to Activate Rutherrin® with Diabetes Drug
Press Release, UncategorizedToronto, Ontario –August 21 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radi...
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
Press Release, NMIBC, PCDs, PrivatePlacementJuly 8, 2024 - Theralase® is pleased to announce that it has successfully closed its first tranche of a Non-Brokered Private Placement ("NBPP") offering ("Offering") of units ("Units")....
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
Press Release, rutherrin, TSXV:TLTJune 20, 2024 - Theralase's, lead drug formulation, Rutherrin® was able to repurpose non-cancer drugs for cancer therapy in preclinical research....
Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically
Press ReleaseJune 19, 2024 - Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer (“NSCLC”) animal model....
Rutherrin® Increases Efficacy of Immunotherapy Preclinically
Press ReleaseJune 18, 2024 - Rutherrin®, in preclinical research, has demonstrated an ability to increase the efficacy of immunotherapy....
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase®
Press ReleaseJune 14, 2024 - Reminder Notice of Annual General and Special Meeting on June 19, 2024 at 4:30 pm after the formal part of the meeting a virtual zoom presentation will follow at 5:30 pm...
Rutherrin® Increases Efficacy of Chemotherapy
Press ReleaseJune 12, 2024 - Rutherrin® has been proven in preclinical studies to enhance the efficacy of chemotherapy and reduce multidrug resistance....
Ruvidar Enhances Efficacy of Cancer Drug
Press ReleaseJune 10, 2024 - Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation....
Theralase® Successfully Destroys Lung Cancer
Press ReleaseJune 6, 2024 - Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”)....
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
